DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection

Information source: Tanta University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatitis C; Lichen Planus; Vasculitis; Autoimmune Diseases

Intervention: Ribavirin (Drug); Betamethasone (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Tanta University

Official(s) and/or principal investigator(s):
Asem A Elfert, MD, Principal Investigator, Affiliation: Tanta Faculty of Medicine, Professor
Fat-heya E Assel, MD, Study Director, Affiliation: Tanta Faculty of Medicine, Professor
Mohamed Y Rabei, Study Director, Affiliation: Dr.
Islam S Ismail, Study Director, Affiliation: Dr.

Overall contact:
Asem A Elfert, MD, Phone: +20-122-437-8188, Email: asem1967@yahoo.com

Summary

This study will be conducted on 30 patients with mucocutaneous complaints and documented HCV infection. The study will be done at Tropical medicine department , Tanta university. It will be conducted between June2014 and November 2014. The aim of the study is to assess efficacy of Ribavirin in the management of mucocutaneous extrahepatic manifestations of HCV infection.

Clinical Details

Official title: Randomized Controlled Study of Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of participants with improved skin manifestations of HCV infection after taking Ribavirin compared with topical steroids.

Detailed description: Hepatitis C virus is a common cause of chronic liver disease worldwide and represent public health problem. The Egyptian Demographic Health Survey (EDHS), a cross sectional survey including hepatitis C virus (HCV) biomarkers, was conducted in 2008 on a large nationally representative sample. It estimated HCV prevalence among the 15-59 years age group to be 14. 7% . Accordingly, Egypt has the highest HCV prevalence in the world. Although HCV is a hepatotropic virus, in some patients the primary manifestations of infection occur outside the liver. There is a growing body of evidence to support the idea that HCV can replicate efficiently in extrahepatic tissues including the Peripheral blood mononuclear cells (PBMC). Autoimmune manifestations are common in patients chronically infected by HCV . These manifestations can be dominant, whereas the hepatic disease can be quiescent or mild. More recently, there has been growing interest in the relationship between HCV and Sjogren's syndrome (SS), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Of those , this article is interested in cutaneous and mucous membrane manifestations where many reports have shown that cutaneous manifestations are often the first signs of chronic HCV infection and these are indicated in 20-40% of the patients presenting to the dermatology clinics, therefore dermatologists must be aware of skin disorders associated with viral infection. The most commonly encountered dermatological manifestations of HCV infection includes mixed cryoglobulinemia (MC), porphyria cutanea tarda (PCT), cutaneous and/or oral lichen planus (LP), urticaria, pruritus, thrombocytopenic purpura and cutaneous vasculitis. Although majority of skin manifestations of chronic HCV infection represent the clinical impression of autoimmune phenomena, however, precise pathogenesis of these extra-hepatic complications is not well understood. The aim of the study is to assess efficacy of Ribavirin in the management of mucocutaneous extrahepatic manifestations of HCV infection This study will be conducted on 30 patients with mucocutaneous complaints and documented HCV infection. The study will be done at Tropical medicine department , Tanta university. It will be conducted between June2014 and November 2014.

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with evidence of HCV infection and mucocutaneous complaint and

contraindicated to have standard antiviral therapy. Exclusion Criteria:

- Hypersensitivity to Ribavirin

- Pregnant & Lactating women

- Male partners of pregnant women

Locations and Contacts

Asem A Elfert, MD, Phone: +20-122-437-8188, Email: asem1967@yahoo.com

Tanta University Hospital, Tanta, Gharbia 31111, Egypt; Recruiting
Asem A Elfert, MD, Phone: +20-122-437-8188, Email: asem1967@yahoo.com
Asem A Elfert, MD, Principal Investigator
Fat-heya E Assel, MD, Sub-Investigator
Mohamed Y Rabei, Sub-Investigator
Islam S Ismail, Sub-Investigator
Additional Information

Starting date: June 2014
Last updated: October 6, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017